featured
Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
J. Clin. Oncol 2022 Jun 04;[EPub Ahead of Print], T Martin, SZ Usmani, JG Berdeja, M Agha, AD Cohen, P Hari, D Avigan, A Deol, M Htut, A Lesokhin, NC Munshi, E O'Donnell, AK Stewart, JM Schecter, JD Goldberg, CC Jackson, TM Yeh, A Banerjee, A Allred, E Zudaire, W Deraedt, Y Olyslager, C Zhou, L Pacaud, D Madduri, A Jakubowiak, Y Lin, S JagannathFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.